Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 19 | 2025 | 686 | 1.580 |
Why?
|
| Analgesics, Opioid | 11 | 2025 | 526 | 1.050 |
Why?
|
| Dietary Supplements | 3 | 2021 | 235 | 0.990 |
Why?
|
| Pharmacy | 2 | 2022 | 17 | 0.990 |
Why?
|
| Education, Pharmacy | 5 | 2020 | 17 | 0.900 |
Why?
|
| Complementary Therapies | 2 | 2018 | 63 | 0.780 |
Why?
|
| Students, Pharmacy | 3 | 2020 | 12 | 0.770 |
Why?
|
| Vaccines | 1 | 2022 | 96 | 0.670 |
Why?
|
| Homes for the Aged | 5 | 2020 | 166 | 0.660 |
Why?
|
| Pharmacists | 7 | 2020 | 130 | 0.650 |
Why?
|
| Drug Utilization | 6 | 2021 | 204 | 0.530 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 459 | 0.530 |
Why?
|
| Hospice Care | 1 | 2018 | 75 | 0.520 |
Why?
|
| Palliative Care | 2 | 2020 | 248 | 0.500 |
Why?
|
| Atrial Fibrillation | 5 | 2025 | 871 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2021 | 214 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 706 | 0.440 |
Why?
|
| Pain | 5 | 2023 | 398 | 0.430 |
Why?
|
| Warfarin | 4 | 2025 | 124 | 0.430 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 765 | 0.420 |
Why?
|
| Aged | 30 | 2026 | 14917 | 0.410 |
Why?
|
| Aged, 80 and over | 21 | 2026 | 5600 | 0.410 |
Why?
|
| Medicare | 10 | 2023 | 622 | 0.400 |
Why?
|
| Humans | 50 | 2026 | 64934 | 0.390 |
Why?
|
| United States | 23 | 2026 | 8082 | 0.390 |
Why?
|
| Stroke | 5 | 2025 | 1208 | 0.370 |
Why?
|
| Anticoagulants | 5 | 2025 | 522 | 0.370 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 80 | 0.360 |
Why?
|
| Aspirin | 2 | 2011 | 171 | 0.360 |
Why?
|
| Activities of Daily Living | 4 | 2021 | 293 | 0.350 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 11 | 0.340 |
Why?
|
| Epilepsy | 2 | 2023 | 113 | 0.320 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 176 | 0.320 |
Why?
|
| Pain Management | 4 | 2024 | 174 | 0.320 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 861 | 0.310 |
Why?
|
| Professional Role | 3 | 2016 | 45 | 0.310 |
Why?
|
| Vitamins | 1 | 2010 | 80 | 0.300 |
Why?
|
| Integrative Medicine | 2 | 2021 | 34 | 0.300 |
Why?
|
| Drug Therapy | 2 | 2010 | 56 | 0.290 |
Why?
|
| Patient Selection | 1 | 2011 | 483 | 0.290 |
Why?
|
| Female | 28 | 2026 | 33915 | 0.290 |
Why?
|
| Computers, Handheld | 2 | 2005 | 37 | 0.290 |
Why?
|
| Physicians | 2 | 2011 | 473 | 0.280 |
Why?
|
| Polypharmacy | 2 | 2026 | 67 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 140 | 0.270 |
Why?
|
| Primary Health Care | 2 | 2011 | 721 | 0.270 |
Why?
|
| Chronic Pain | 3 | 2024 | 150 | 0.270 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 3 | 0.260 |
Why?
|
| Hospitalization | 5 | 2025 | 1383 | 0.260 |
Why?
|
| Professional-Patient Relations | 1 | 2008 | 126 | 0.250 |
Why?
|
| Attitude of Health Personnel | 2 | 2011 | 625 | 0.250 |
Why?
|
| Gastric Bypass | 1 | 2007 | 69 | 0.250 |
Why?
|
| Delirium | 2 | 2025 | 55 | 0.240 |
Why?
|
| Central Nervous System Agents | 1 | 2026 | 11 | 0.240 |
Why?
|
| Anticonvulsants | 3 | 2023 | 103 | 0.230 |
Why?
|
| Algorithms | 1 | 2011 | 1039 | 0.230 |
Why?
|
| Cross-Sectional Studies | 10 | 2026 | 2701 | 0.230 |
Why?
|
| Administration, Oral | 5 | 2025 | 371 | 0.230 |
Why?
|
| Male | 24 | 2026 | 30942 | 0.220 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 164 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2025 | 88 | 0.220 |
Why?
|
| Community Health Services | 1 | 2005 | 126 | 0.210 |
Why?
|
| Communication | 2 | 2012 | 595 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6840 | 0.200 |
Why?
|
| Clonazepam | 1 | 2023 | 3 | 0.200 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 9 | 0.200 |
Why?
|
| Rivaroxaban | 2 | 2023 | 19 | 0.190 |
Why?
|
| Dabigatran | 2 | 2023 | 20 | 0.190 |
Why?
|
| Analgesics | 2 | 2021 | 102 | 0.190 |
Why?
|
| Embolism | 1 | 2023 | 41 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 36 | 0.180 |
Why?
|
| Fractures, Bone | 2 | 2025 | 138 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 165 | 0.180 |
Why?
|
| Immunization | 1 | 2022 | 135 | 0.180 |
Why?
|
| Heart Failure | 3 | 2017 | 948 | 0.180 |
Why?
|
| Neuralgia | 1 | 2021 | 21 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2023 | 158 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 795 | 0.170 |
Why?
|
| Oxycodone | 2 | 2018 | 28 | 0.160 |
Why?
|
| Prevalence | 5 | 2026 | 1439 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 91 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 152 | 0.160 |
Why?
|
| Vaccination | 1 | 2022 | 375 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2019 | 7 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 126 | 0.150 |
Why?
|
| Cancer Pain | 1 | 2019 | 17 | 0.150 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 256 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2017 | 63 | 0.150 |
Why?
|
| Program Development | 2 | 2018 | 208 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.140 |
Why?
|
| Medicare Part D | 4 | 2020 | 36 | 0.140 |
Why?
|
| Self Care | 1 | 2020 | 215 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2011 | 2093 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2023 | 2612 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2020 | 439 | 0.120 |
Why?
|
| Morphine | 1 | 2016 | 60 | 0.120 |
Why?
|
| Fentanyl | 1 | 2016 | 66 | 0.120 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 120 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 341 | 0.120 |
Why?
|
| Biological Products | 1 | 2016 | 92 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2019 | 418 | 0.110 |
Why?
|
| Middle Aged | 9 | 2025 | 18203 | 0.110 |
Why?
|
| Internet | 3 | 2012 | 466 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2023 | 279 | 0.110 |
Why?
|
| Biomedical Research | 2 | 2007 | 260 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2018 | 727 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1600 | 0.100 |
Why?
|
| Videodisc Recording | 1 | 2012 | 8 | 0.100 |
Why?
|
| Community Pharmacy Services | 1 | 2012 | 12 | 0.100 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2012 | 21 | 0.090 |
Why?
|
| Interprofessional Relations | 2 | 2018 | 137 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 735 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 739 | 0.090 |
Why?
|
| Software Design | 1 | 2011 | 28 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 1113 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2012 | 128 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1557 | 0.090 |
Why?
|
| Health Education | 1 | 2012 | 188 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 174 | 0.080 |
Why?
|
| Accidental Falls | 2 | 2025 | 128 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 73 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2011 | 154 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 258 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 481 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 856 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 23 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 991 | 0.070 |
Why?
|
| Ethics, Pharmacy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2008 | 71 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 5775 | 0.070 |
Why?
|
| Tramadol | 2 | 2018 | 14 | 0.070 |
Why?
|
| Drug Industry | 1 | 2008 | 41 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 767 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2482 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2005 | 309 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 555 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 142 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 97 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 260 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2005 | 60 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 26 | 0.050 |
Why?
|
| Lorazepam | 1 | 2023 | 8 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 405 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 10 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 24 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 3753 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2023 | 106 | 0.050 |
Why?
|
| South Dakota | 1 | 2002 | 4 | 0.050 |
Why?
|
| Mississippi | 1 | 2002 | 15 | 0.050 |
Why?
|
| Maine | 1 | 2002 | 18 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5406 | 0.050 |
Why?
|
| New York | 1 | 2002 | 144 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2005 | 881 | 0.050 |
Why?
|
| Medical Informatics | 2 | 2012 | 72 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 165 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 202 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 460 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 117 | 0.040 |
Why?
|
| Prognosis | 2 | 2005 | 1775 | 0.040 |
Why?
|
| Societies, Pharmaceutical | 2 | 2012 | 2 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 57 | 0.040 |
Why?
|
| Curriculum | 2 | 2018 | 607 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 111 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 2020 | 16 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1415 | 0.040 |
Why?
|
| Prescription Drug Misuse | 1 | 2020 | 20 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 158 | 0.040 |
Why?
|
| Pregnancy | 1 | 2007 | 2371 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 75 | 0.040 |
Why?
|
| Analgesia | 1 | 2020 | 36 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 141 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 496 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 189 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 233 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 69 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 288 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2018 | 164 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 96 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 160 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 374 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 343 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 5 | 0.030 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 27 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 741 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 31 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 109 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 168 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 284 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 179 | 0.030 |
Why?
|
| Adult | 2 | 2012 | 17306 | 0.030 |
Why?
|
| Research Design | 2 | 2008 | 585 | 0.020 |
Why?
|
| Buprenorphine | 1 | 2016 | 198 | 0.020 |
Why?
|
| Pharmacology, Clinical | 1 | 2012 | 3 | 0.020 |
Why?
|
| Medication Reconciliation | 1 | 2012 | 14 | 0.020 |
Why?
|
| Cultural Diversity | 1 | 2012 | 54 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 918 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 899 | 0.020 |
Why?
|
| Logistic Models | 2 | 2005 | 1268 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 202 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 223 | 0.020 |
Why?
|
| Geriatrics | 1 | 2010 | 50 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2012 | 387 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 164 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 213 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2012 | 463 | 0.020 |
Why?
|
| Confidentiality | 1 | 2008 | 58 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2008 | 38 | 0.020 |
Why?
|
| Disclosure | 1 | 2008 | 57 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2007 | 59 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2007 | 91 | 0.020 |
Why?
|
| Organizational Innovation | 1 | 2007 | 83 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 105 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 178 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2007 | 488 | 0.010 |
Why?
|
| Bias | 1 | 2004 | 115 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 497 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 124 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 576 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 610 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2759 | 0.010 |
Why?
|